Kestra Medical Technologies opened lower at $31.34, compared with its previous close of $31.63. In the last trading session, the stock traded between - and -. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Kestra Medical Technologies is now worth
$ 130.88
Giving a profit of
$ 30.88 (30.88%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-3.05 (-9.63%)
Day High
-
Day Low
-
Day Open
$31.34
Prev Close
$31.63
Volume
4,63,897
1W Return
-6.40%
1M Return
6.04%
3M Return
2.55%
6M Return
30.94%
1Y Return
3.72%
Fundamentals
Market Cap ($ Mn)
1,703
PE Ratio
-
PB Ratio
5.76
PEG Ratio
-
ROE
-
ROCE
-101.48%
EPS (TTM)
-
Investment Returns
1 Week
-6.40%
1 Month
6.04%
3 Months
2.55%
6 Months
30.94%
9 Months
2.64%
Financials
Quarterly
All values in $ Mn
17.2
Apr 25
19.4
Jul 25
22.6
Oct 25
24.6
Jan 26
28.6
Apr 26
31.0
Jul 26
Updates
20Oct
Evercore initiates Kestra Medical with Outperform, $34 price target
Evercore ISI Group initiated coverage on Kestra Medical Technologies. Analyst Vijay Kumar assigned an Outperform rating. Price target set at $34 per share.
23 days ago
1Sep
Kestra Medical Q1FY27 Results: Earnings report due Sept 14
Kestra Medical Technologies (NASDAQ: KMTS) to report Q1FY27 results on September 14. Conference call scheduled for 4:30 p.m. ET following market close. Live webcast available via investor relations website.
2mo ago
26Aug
Kestra appoints Curtis Kopf as SVP of customer experience
Kestra appoints Curtis Kopf as Senior Vice President of Customer Experience. Role created to lead patient journey for ASSURE WCD from order to return. Kopf previously led global CX at Insulet Corp and digital ops at REI. Appointment supports AI-driven investments in commercial capabilities.
2mo ago
21Jul
Oppenheimer initiates coverage on Kestra Medical Techs
Oppenheimer analyst Suraj Kalia initiates coverage on Kestra Medical Techs with a Perform rating, indicating a neutral market outlook.
3mo ago
15Jul
BTIG raises Kestra Medical Techs price target to $32
BTIG analyst Marie Thibault has maintained a Buy rating on Kestra Medical Techs and raised the price target from $30 to $32.
4mo ago
15Jul
Kestra secures $200M term loan with Pharmakon Advisors
Kestra Medical Technologies secured a $200M five-year term loan facility with Pharmakon Advisors, LP, featuring 48 months of interest-only payments and a SOFR plus 5.5% interest rate. The facility includes four tranches, with $75 million funded immediately to retire existing debt and additional tranches available through 2028 contingent on revenue milestones. Kestra reported total liquidity of approximately $357 million as of April 30, 2026.
